Publication details

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration

Authors

KAYSER S. ELLIOTT M. A. LUSKIN M. BRUNNER A. M. KRAMER M. RÁČIL Zdeněk NOVÁKOVÁ Zuzana CETKOVSKY P. NOVAK J. STOELZEL F. THIEDE C. MULLER-TIDOW C. PLATZBECKER U. ROLLIG C. SCHLENK R. F. LEVIS M. J.

Year of publication 2019
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description Core binding factor acute myeloid leukemia (CBF-AML) is defined by the presence of either t(8;21)(q22;q22) or inv(16)(p13.1q22)/t(16;16)(p13.1;q22) and is associated with a favorable outcome, particularly if treated with repetitive cycles of high-dose cytarabine as post-remission therapy. Long-time 10-year overall survival (OS) rate was reported of 58% in FLT3-ITD negative patients (pts; Allen et al. Leukemia 2013). Nevertheless, 30-40% CBF-AML pts experience relapse. FLT3-ITD mutations occur in roughly 5-10% of adult CBF-AML. However, their prognostic relevance is still controversial.

You are running an old browser version. We recommend updating your browser to its latest version.

More info